Stated plainly: 97.1% · sampling plan.
I would like help reading this properly rather than being told what conclusion to reach.
I have the full report including the method section, so I can quote specifics if that helps.
What can I legitimately conclude from this figure?
97.1 per cent is a statement about area, and the other 2.9 per cent is everything the detector saw and did not assign to your peak. Read it as 97.1 of every 100 units of peak area at whatever wavelength was used, not as 97.1 per cent of the mass in the vial. With the sampling plan attached you can at least see how the figure was produced, which is the difference between a measurement and a claim. What it still does not tell you is content: how many milligrams are actually there.
The single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.
Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
| Test | Answers | Does NOT answer |
|---|---|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.
Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.
If you are ranking vendors, specify a method and have all samples tested at the same place.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemThe short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.
Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.
The relevant detail is that buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.
One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
Identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.
Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.
Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
Compare purity within a single laboratory on the same method, never across laboratories.
Gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.
The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
edited 24 Nov 2025 by gradient_slope — added the placebo-arm figures
Stated carefully, area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.
Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
edited 10 Dec 2025 by RP_C18 — updated for the 2026 guidance change
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.